Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

PHASE1CompletedINTERVENTIONAL
Enrollment

486

Participants

Timeline

Start Date

February 2, 2016

Primary Completion Date

September 14, 2017

Study Completion Date

September 14, 2017

Conditions
Malaria, Vivax
Interventions
DRUG

Tafenoquine 150 mg

Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.

DRUG

Matched placebo 150mg

It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.

Trial Locations (3)

21225

GSK Investigational Site, Baltimore

66211

GSK Investigational Site, Overland Park

91206

GSK Investigational Site, Glendale

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Medicines for Malaria Venture

OTHER

lead

GlaxoSmithKline

INDUSTRY

NCT02658435 - Assessment of Any Potential Retinal Effects of Tafenoquine (TQ) | Biotech Hunter | Biotech Hunter